OREANDA-NEWS. December 12, 2012. Sales for the first nine months of 2012 amounted to RUR 4,151.4 mln. The share of product segments in OJSC “Veropharm” sales is as follows:

Group of pharmaceutical products

Rx drugs sales amounted to RUR 2,819.6 mln. The Rx drugs sales made 62.2% of total sales of the Company;

OTC drugs sales amounted to RUR 577.6 mln. The OTC drugs sales made 12.7% of total sales of the Company.

Traditional drugs sales amounted to RUR 15.8 mln which is 29.9 % less than for the same period of 2011. The traditional drugs sales made 0.3% of total sales of the Company.

Group of non-pharmaceutical products

Non-pharmaceutical products sales made RUR 738.4 mln, which corresponds to 17.8% of total sales of the Company.

Under the Federal Reimbursement Program (FRP) Veropharm’s sales amounted to RUR 68.1 mln according to the results of the first nine months of 2012, which corresponds to 1.6% of the Company’s total sales.

The Russian Federation is the main market and ensures 95.2% of the Company's sales. For the first nine months of 2012 the Company exported 4.8% of its products.

PROFIT

In the first nine months of 2012 the gross profit of OJSC “Veropharm” amounted to RUR 2,979.9 mln. The gross profit ratio for the first nine months of 2012 made 71.8% against 69.2% for the first nine months in 2011. The gross profit ratio of the segments of OJSC “Veropharm” is as stated:

Group of pharmaceutical products

In relation to Rx drugs it made 73.8% for the first nine months of 2012 against 69.8% for the first nine months of2011;

In relation to OTC drugs it made 69.4% for the first nine months of 2012 against 73.7% for the first nine months of 2011;

In relation to traditional products it made 56.8% for the first nine months of 2012 against 44.4% for the first nine months of 2011.

Group of non-pharmaceutical products

In relation to non-pharmaceutical products it increased from 64.1% in the first nine months of 2011 to 66.3% in the first nine months of 2012.

For the first nine months of 2012 EBITDA amounted to RUR 1,351.9 mln as compared to RUR 1,338.1 mln in the first nine months of 2011. EBITDA to sales ratio made 32.6% for the first nine months of 2012 against 29.5% of the previous period.

Net profit for the reporting period amounted to RUR 937.7 mln.

FACILITIES INVESTMENTS

In the first nine months of 2012 amount of investments assigned for modernization and equipment of the main production facilities of the Company made RUR 623.4 mln.

DEBT

As at September 30, 2012 the debt of OJSC “Veropharm” amounted to RUR 1,578.5 mln making no more than 20% of the Company’s net assets value.